Andelyn Biosciences Collaborates with Grace Science to Further Develop GS-100

Partnership for Progress: Grace Science and Andelyn Biosciences Collaborate on GS-100 Manufacture and Expedite Delivery to Patients with NGLY1 Deficiency

Grace Science LLC and Andelyn Biosciences Inc., a cell and gene therapy Contract Development and Manufacturing Organization (CDMO), have announced a partnership to tech transfer and manufacture GS-100. GS-100 is a suspension process AAV NGLY1 gene therapy intended for Phase I/II/III clinical trial material for the treatment of NGLY1 Deficiency.

NGLY1 Deficiency is a severe, life-threatening disease that currently has no approved therapy. Individuals with NGLY1 Deficiency endure debilitating symptoms throughout their lives. The collaboration between Grace Science and Andelyn Biosciences aims to improve efficiency, support ongoing clinical trials, and expedite the delivery of this crucial therapy to patients.

In 2021, GS-100 received orphan drug designation (ODD) from the FDA and the European Medicine Agency (EMA). Additionally, the FDA granted GS-100 Rare Pediatric Disease Designation in 2021. These designations open the possibility for Priority Review Voucher upon marketing approval and Fast-Track designation in 2023. Grace Science successfully administered the first dose of GS-100 to an NGLY1 Deficiency patient in February 2024, with plans to dose the second patient in May of that year.

Through this partnership, Grace Science will utilize Andelyn’s expertise in AAV processes and capabilities in late-stage manufacturing and commercial readiness. This collaboration accelerates Grace’s manufacturing timelines, offering hope to individuals suffering from NGLY1 Deficiency.

Matt Wilsey, CEO and Co-Founder of Grace Science, conveyed excitement about the partnership with Andelyn Biosciences, highlighting the company’s expertise in AAV gene therapy manufacturing. He emphasized that Andelyn’s capabilities will ensure that NGLY1 patients have access to a safe, high-quality drug product for clinical trials and beyond. Matt Niloff, Chief Commercial Officer at Andelyn Biosciences expressed gratitude for this opportunity to collaborate with Grace Science while emphasizing shared values of strong collaboration


As a content writer at, I am Samantha Johnson—a wordsmith with a fervent love for storytelling and a keen eye for captivating readers. With a diverse background in journalism and digital marketing, I craft compelling narratives that engage, inform, and inspire our audience. Whether unraveling breaking news stories or delving into thought-provoking features, my aim is to deliver content that resonates and leaves a lasting impact. Join me on a journey through the ever-evolving landscape of news and narratives at